JP2005508165A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508165A5 JP2005508165A5 JP2003534444A JP2003534444A JP2005508165A5 JP 2005508165 A5 JP2005508165 A5 JP 2005508165A5 JP 2003534444 A JP2003534444 A JP 2003534444A JP 2003534444 A JP2003534444 A JP 2003534444A JP 2005508165 A5 JP2005508165 A5 JP 2005508165A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- amino acids
- polynucleotide
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 96
- 108090000765 processed proteins & peptides Proteins 0.000 claims 96
- 102000004196 processed proteins & peptides Human genes 0.000 claims 96
- 150000001413 amino acids Chemical class 0.000 claims 95
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 58
- 102000040430 polynucleotide Human genes 0.000 claims 41
- 108091033319 polynucleotide Proteins 0.000 claims 41
- 239000002157 polynucleotide Substances 0.000 claims 41
- 230000014511 neuron projection development Effects 0.000 claims 24
- 102000005781 Nogo Receptor Human genes 0.000 claims 22
- 108020003872 Nogo receptor Proteins 0.000 claims 22
- 230000001404 mediated effect Effects 0.000 claims 22
- 230000005764 inhibitory process Effects 0.000 claims 19
- 239000012634 fragment Substances 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 4
- 102000005720 Glutathione transferase Human genes 0.000 claims 4
- 108010070675 Glutathione transferase Proteins 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 208000016192 Demyelinating disease Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 206010052428 Wound Diseases 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 230000003376 axonal effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 210000002569 neuron Anatomy 0.000 claims 3
- 230000008929 regeneration Effects 0.000 claims 3
- 238000011069 regeneration method Methods 0.000 claims 3
- -1 antibody Substances 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 208000011403 Alexander disease Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000022526 Canavan disease Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 208000028226 Krabbe disease Diseases 0.000 claims 1
- 208000034800 Leukoencephalopathies Diseases 0.000 claims 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 claims 1
- 206010056332 Panencephalitis Diseases 0.000 claims 1
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 claims 1
- 102100029826 Reticulon-4 receptor Human genes 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000036546 leukodystrophy Diseases 0.000 claims 1
- 230000003458 metachromatic effect Effects 0.000 claims 1
- 238000000520 microinjection Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000023105 myelination Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 208000023516 stroke disease Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 210000004885 white matter Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/972,599 US7119165B2 (en) | 2000-01-12 | 2001-10-06 | Nogo receptor-mediated blockade of axonal growth |
| PCT/US2002/032007 WO2003031462A2 (en) | 2001-10-06 | 2002-10-04 | Nogo receptor-mediated blockade of axonal growth |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005508165A JP2005508165A (ja) | 2005-03-31 |
| JP2005508165A5 true JP2005508165A5 (enExample) | 2006-01-05 |
| JP4383869B2 JP4383869B2 (ja) | 2009-12-16 |
Family
ID=25519870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003534444A Expired - Fee Related JP4383869B2 (ja) | 2001-10-06 | 2002-10-04 | 軸索成長のnogoのレセプターを仲介とした妨害 |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US7119165B2 (enExample) |
| EP (1) | EP1451337A4 (enExample) |
| JP (1) | JP4383869B2 (enExample) |
| AU (1) | AU2002334889B2 (enExample) |
| CA (1) | CA2461655A1 (enExample) |
| WO (1) | WO2003031462A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2264174A3 (en) * | 1998-07-22 | 2012-03-07 | SmithKline Beecham Limited | Protein similar to neuroendocrine-specific protein, and encoding CDNA |
| US7119165B2 (en) | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
| DE60141409D1 (de) * | 2000-10-06 | 2010-04-08 | Biogen Idec Inc | Homologe des nogo rezeptors |
| US7309485B2 (en) * | 2001-12-03 | 2007-12-18 | Children's Medical Center Corporation | Reducing myelin-mediated inhibition of axon regeneration |
| US7745151B2 (en) * | 2002-08-02 | 2010-06-29 | Children's Medical Center Corporation | Methods of determining binding between Nogo receptor and p75 neurotrophin receptor |
| MXPA05001615A (es) * | 2002-08-10 | 2005-08-19 | Biogen Idec Inc | Antagonistas del nogo receptor. |
| JP2006526382A (ja) * | 2002-12-06 | 2006-11-24 | シンガポール ジェネラル ホスピタル ピーティーイー リミテッド | 中枢神経系の損傷 |
| US7842666B2 (en) * | 2002-12-20 | 2010-11-30 | Research Foundation Of City University Of New York | Inhibitors of myelin-associated glycoprotein (MAG) activity for regulating neural growth and regeneration |
| EP2248899B8 (en) | 2003-03-19 | 2015-07-15 | Biogen MA Inc. | NOGO receptor binding protein |
| US7541335B2 (en) * | 2003-04-04 | 2009-06-02 | University Of Rochester | Nogo-receptors and methods of use |
| AU2004231742A1 (en) * | 2003-04-16 | 2004-11-04 | Biogen Idec Ma Inc. | Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques |
| CN101410130A (zh) * | 2003-05-15 | 2009-04-15 | 利兰·斯坦福青年大学托管委员会 | 新颖的免疫调节肽 |
| US20080274112A1 (en) * | 2003-08-07 | 2008-11-06 | Lee Daniel H S | Nogo Receptor Antagonists |
| WO2005059515A2 (en) * | 2003-12-16 | 2005-06-30 | Children's Medical Center Corporation | Method for treating neurological disorders |
| US8912144B2 (en) * | 2003-12-16 | 2014-12-16 | Children's Medical Center Corporation | Method for treating stroke via administration of NEP1-40 and inosine |
| AU2005210621B2 (en) * | 2004-01-30 | 2009-10-01 | Biogen Idec Ma Inc. | Treatment of conditions involving dopaminergic neuronal degeneration using nogo receptor antagonists |
| JP2008500064A (ja) * | 2004-05-21 | 2008-01-10 | ザ ユーエービー リサーチ ファウンデーション | 可変性リンパ球受容体、その関連ポリペプチドおよび核酸、ならびにその使用 |
| EP2474317A1 (en) | 2004-06-24 | 2012-07-11 | Biogen Idec MA Inc. | Treatment of conditions involving demyelination |
| WO2006017673A2 (en) | 2004-08-03 | 2006-02-16 | Biogen Idec Ma Inc. | Taj in neuronal function |
| WO2006047049A2 (en) * | 2004-10-01 | 2006-05-04 | Yale University | Nogo-a polypeptide fragments, variant nogo receptor-1 polypeptides, and uses thereof |
| WO2006056998A2 (en) * | 2004-11-29 | 2006-06-01 | Yeda Research And Development Co. Ltd. | Methods of cell therapy, neurogenesis and oligodendrogenesis |
| EP1904091A4 (en) * | 2005-07-07 | 2009-12-23 | Univ Yale | COMPOSITIONS AND METHODS FOR SUPPRESSING THE INHIBITION OF AXON GROWTH |
| WO2007008547A2 (en) | 2005-07-08 | 2007-01-18 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| WO2007014382A1 (en) * | 2005-07-28 | 2007-02-01 | Wyeth | Compositions and methods of mutant nogo-66 domain proteins |
| US9216212B2 (en) * | 2005-08-05 | 2015-12-22 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| WO2007025219A2 (en) * | 2005-08-25 | 2007-03-01 | Biogen Idec Ma Inc. | Nogo receptor polypeptides and polypeptide fragments and uses thereof |
| EP1928905B1 (de) * | 2005-09-30 | 2015-04-15 | AbbVie Deutschland GmbH & Co KG | Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung |
| WO2007089601A2 (en) | 2006-01-27 | 2007-08-09 | Biogen Idec Ma Inc. | Nogo receptor antagonists |
| EP2023735A4 (en) * | 2006-05-15 | 2011-05-25 | Biogen Idec Inc | USE OF ANTAGONISTS OF THE NOGO RECEPTOR 1 (NGR1) TO PROMOTE THE SURVIVAL OF OLIGODENDROCYTES |
| EP2046828A2 (en) * | 2006-07-07 | 2009-04-15 | Wyeth | Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same |
| US8642040B2 (en) | 2006-07-24 | 2014-02-04 | Biogen Idec Ma Inc. | Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of Sp35 or TrkA antagonists |
| JP2010502623A (ja) * | 2006-08-31 | 2010-01-28 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Nogoレセプターポリペプチドの末梢投与に関する方法 |
| CA2701189C (en) * | 2007-10-11 | 2017-05-16 | Biogen Idec Ma Inc. | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists |
| WO2009061500A1 (en) * | 2007-11-08 | 2009-05-14 | Biogen Idec Ma Inc. | Use of lingo-4 antagonists in the treatment of conditions involving demyelination |
| WO2009073141A2 (en) * | 2007-11-28 | 2009-06-11 | Strittmatter Stephen M | Nogo receptor binding small molecules to promote axonal growth |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| US8992918B2 (en) * | 2008-03-13 | 2015-03-31 | Yale University | Reactivation of axon growth and recovery in chronic spinal cord injury |
| JP2011527572A (ja) | 2008-07-09 | 2011-11-04 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Lingo抗体または断片を含む組成物 |
| WO2010039224A2 (en) | 2008-09-30 | 2010-04-08 | University Of Massachusetts Medical School | Respiratory syncytial virus (rsv) sequences for protein expression and vaccines |
| KR20120118002A (ko) | 2009-12-08 | 2012-10-25 | 애보트 게엠베하 운트 콤파니 카게 | 망막 신경 섬유 층 변성의 치료에 사용하기 위한 rgm a 단백질에 대한 모노클로날 항체 |
| PE20190907A1 (es) | 2012-01-27 | 2019-06-26 | AbbVie Deutschland GmbH and Co KG | Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas |
| JP2015518829A (ja) | 2012-05-14 | 2015-07-06 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 運動ニューロンに関する状態の処置のためのlingo−2アンタゴニスト |
| AU2016205197B2 (en) | 2015-01-08 | 2021-10-21 | Biogen Ma Inc. | LINGO-1 antagonists and uses for treatment of demyelinating disorders |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341050C (en) * | 1988-11-04 | 2000-07-11 | Martin E. Schwab | Neurite growth regulatory factors |
| AU652537B2 (en) * | 1988-11-04 | 1994-09-01 | Erziehungsdirektion Of The Canton Zurich | Neurite growth regulatory factors |
| US5250414A (en) * | 1988-11-04 | 1993-10-05 | Erziehungsdirektion Of The Canton Zurich | Diagnostic methods using neurite growth regulatory factors |
| WO2000073452A2 (en) | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US5858708A (en) | 1996-08-12 | 1999-01-12 | Bandman; Olga | Polynucleotides encoding two novel human neuroendocrine-specific proteins |
| US7368531B2 (en) * | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
| WO1999066041A1 (en) | 1998-06-16 | 1999-12-23 | Human Genome Sciences, Inc. | 94 human secreted proteins |
| WO2000070050A1 (en) | 1999-05-14 | 2000-11-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| DK1490386T3 (da) | 1998-03-10 | 2008-12-15 | Genentech Inc | Nyt polypeptid og nukleinsyrer kodende for dette |
| US6962797B2 (en) * | 1998-04-15 | 2005-11-08 | Genentech, Inc. | Nucleic acids encoding PRO615 |
| EP2264174A3 (en) | 1998-07-22 | 2012-03-07 | SmithKline Beecham Limited | Protein similar to neuroendocrine-specific protein, and encoding CDNA |
| HUP0301829A3 (en) | 1998-11-06 | 2009-03-30 | Schwab | Nucleotidok and protein sequences of nogo genes and methods based thereon |
| US6152155A (en) | 1998-11-30 | 2000-11-28 | Milligan; Lon | Filter cleaning device |
| ATE458050T1 (de) | 1998-12-01 | 2010-03-15 | Genentech Inc | Promotion oder inhibition von angiogenese und kardiovaskularisation |
| JP3993746B2 (ja) | 1998-12-22 | 2007-10-17 | ジェネンテック・インコーポレーテッド | 腫瘍性細胞成長阻害のための組成物及び方法 |
| US7041474B2 (en) | 1998-12-30 | 2006-05-09 | Millennium Pharmaceuticals, Inc. | Nucleic acid encoding human tango 509 |
| KR20010103046A (ko) | 1999-03-08 | 2001-11-17 | 제넨테크, 인크. | 면역 관련 질환 치료용 조성물 및 치료 방법 |
| AU2883600A (en) | 1999-03-08 | 2000-09-28 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| JP2004507202A (ja) | 1999-03-31 | 2004-03-11 | キュラジェン コーポレイション | ポリペプチドをコードするオープンリーディングフレームを含む核酸;「orfx」 |
| AU6394400A (en) | 1999-07-30 | 2001-02-19 | Millennium Pharmaceuticals, Inc. | Secreted proteins and uses thereof |
| PL356887A1 (en) | 2000-01-12 | 2004-07-12 | Yale University | Nogo receptor-mediated blockade of axonal growth |
| US7119165B2 (en) * | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
| DE60141409D1 (de) * | 2000-10-06 | 2010-04-08 | Biogen Idec Inc | Homologe des nogo rezeptors |
| JP2005507246A (ja) | 2001-08-27 | 2005-03-17 | ノバルティス アクチエンゲゼルシャフト | Nogoレセプターホモログおよびそれらの使用 |
| JP2005519584A (ja) * | 2001-10-22 | 2005-07-07 | ノバルティス アクチエンゲゼルシャフト | Nogoレセプターホモログおよびそれらの使用 |
| US7309485B2 (en) * | 2001-12-03 | 2007-12-18 | Children's Medical Center Corporation | Reducing myelin-mediated inhibition of axon regeneration |
| US20030113325A1 (en) * | 2001-12-03 | 2003-06-19 | Zhigang He | Reducing myelin-mediated inhibition of axon regeneration |
| EP1354892A1 (en) | 2002-04-19 | 2003-10-22 | Centre National De La Recherche Scientifique (Cnrs) | Peptides capable of inducing attraction of the axonal growth and their use for treating neurodegenerative diseases |
| US7745151B2 (en) * | 2002-08-02 | 2010-06-29 | Children's Medical Center Corporation | Methods of determining binding between Nogo receptor and p75 neurotrophin receptor |
| MXPA05001615A (es) * | 2002-08-10 | 2005-08-19 | Biogen Idec Inc | Antagonistas del nogo receptor. |
| AU2004231742A1 (en) * | 2003-04-16 | 2004-11-04 | Biogen Idec Ma Inc. | Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques |
| US20080274112A1 (en) | 2003-08-07 | 2008-11-06 | Lee Daniel H S | Nogo Receptor Antagonists |
| CA2535007A1 (en) | 2003-08-07 | 2005-02-24 | Biogen Idec Ma Inc. | Nogo receptor antagonists |
| AU2005210621B2 (en) | 2004-01-30 | 2009-10-01 | Biogen Idec Ma Inc. | Treatment of conditions involving dopaminergic neuronal degeneration using nogo receptor antagonists |
| US8992918B2 (en) | 2008-03-13 | 2015-03-31 | Yale University | Reactivation of axon growth and recovery in chronic spinal cord injury |
-
2001
- 2001-10-06 US US09/972,599 patent/US7119165B2/en not_active Expired - Lifetime
-
2002
- 2002-10-04 AU AU2002334889A patent/AU2002334889B2/en not_active Ceased
- 2002-10-04 CA CA002461655A patent/CA2461655A1/en not_active Abandoned
- 2002-10-04 EP EP02800939A patent/EP1451337A4/en not_active Withdrawn
- 2002-10-04 JP JP2003534444A patent/JP4383869B2/ja not_active Expired - Fee Related
- 2002-10-04 WO PCT/US2002/032007 patent/WO2003031462A2/en not_active Ceased
-
2006
- 2006-09-06 US US11/516,024 patent/US20080219984A1/en not_active Abandoned
-
2010
- 2010-01-26 US US12/693,940 patent/US8394929B2/en not_active Expired - Fee Related
-
2013
- 2013-03-07 US US13/788,923 patent/US20130171157A1/en not_active Abandoned
- 2013-11-22 US US14/088,158 patent/US20140178392A1/en not_active Abandoned
-
2015
- 2015-07-13 US US14/798,125 patent/US20170174763A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005508165A5 (enExample) | ||
| JP2003519481A5 (enExample) | ||
| JP6807893B2 (ja) | α−シヌクレインを認識するヒト化抗体 | |
| KR101681910B1 (ko) | Rgm a 단백질에 대한 모노클로날 항체 및 이의 용도 | |
| ES2272093T5 (es) | Composiciones y métodos para incrementar la mineralización de la substancia ósea | |
| US9133272B2 (en) | Bispecific binding agents | |
| EP1181318B1 (en) | Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules | |
| JPH11170A5 (enExample) | ||
| AU2018225493B2 (en) | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases | |
| KR101484025B1 (ko) | 염증성 질환의 치료를 위한 cxcl13 길항제 및 이의 용도 | |
| CA2872928C (en) | Use of semaphorin-4d binding molecules to promote neurogenesis following stroke | |
| HRP20180516T1 (hr) | Humanizirana protutijela specifična za protofibrilni oblik amiloidnog-beta peptida | |
| JP2009520691A5 (enExample) | ||
| EA014525B1 (ru) | Антитела к склеростину и способы их применения | |
| EA015166B1 (ru) | Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител | |
| JP2019527194A5 (enExample) | ||
| JP2008509658A5 (enExample) | ||
| RS57315B1 (sr) | Humanizovana antitela koja prepoznaju alfa-sinuklein | |
| KR20240046648A (ko) | 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법 | |
| JP2008509152A5 (enExample) | ||
| JP2020517262A5 (enExample) | ||
| JPH08504086A (ja) | 背側組織作用因子及び組成物 | |
| JP2012508027A5 (enExample) | ||
| AU2010209273A1 (en) | Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders | |
| RU2007146455A (ru) | Варианты эритропоэтина |